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plantation, Weisdorf et al. report the results of a Center for
International Bone and Marrow Transplant Researche
Eurocord analysis of 740 patients with acute myeloid
leukemia over age 50 undergoing either 8/8 HLA-matched
unrelated donor (MUD), 7/8-matched unrelated donor, or
umbilical cord blood transplantation (UCBT) [1]. The results
are encouraging, with 30% to 40% of patients long-term
survivors with this approach. Similar to results seen in
younger patients, engraftment was slower for UCBT re-
cipients and graft-versus-host disease incidence was higher
after the 7/8 MUD [2]. Leukemia-free survival at 3 years,
adjusted for cytogenetic risk and age, was slightly higher for
8/8 MUD patients (39%) and comparable between UCBT
(28%) and 7/8 MUD (34%).
The 2 major points of the paper are the importance of
allogeneic hematopoietic cell transplantation (HCT) as a
curative approach in this group of patients and the use of
umbilical cord blood or a mismatched unrelated donor as
transplantation donor options. Acute myeloid leukemia in
older patients has traditionally had a very poor prognosis [3].
Cure rates have been estimated between 10% to 20% for pa-
tients over age 60. In addition, many oncologists may be
reluctant to refer older patients for HCT because of concern
over poor tolerance of aggressive regimens, lack of social
supports, or perhaps resource utilization in a ﬁscally con-
strained health care system [4]. Advances in transplantation
over the last 10 years have led to a signiﬁcant decrease in the
mortality of transplantation for all patients [5]. This study by
Weisdorf et al. illustrates that allogeneic HCT is a curative
procedure for patients in ﬁrst complete remission, and
approximately one third of patients, albeit highly selected,
are cured with this approach.
The second conclusion of this paper is that the lack of a
fully matched sibling donor does not preclude a potentially
curative allogeneic HCT. Although the paper did not compare
outcomes withmatched sibling donor HCT, 3-year survival ofFinancial disclosure: See Acknowledgments on page 749.
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ing matched sibling donor HCT [6]. For the many patients,
particularly minority patients, who do not have a MUD
donor, UCB and 7/8 MUD are viable options, with results
slightly less favorable than with MUD. These results differ
from other published studies showing comparable survival
between MUD and double UCBT in both the myeloablative
and reduced-intensity setting [7,8]. One explanation may be
the older age of patients in the current analysis.
The study by Weisdorf et al. does not tell us which donor
source is better for an individual patient: UCB or 7/8 MUD.
Results appear comparable, and perhaps a lower incidence of
graft-versus-host disease with UCBT may be favorable for
some patients. Haploidentical transplantation, UCBT, and
mismatched unrelated donors are all viable options for older
patients without matched related or unrelated donors [9].
The Clinical Trials Network is investigating this questionwith
a randomized study of UCBT versus haploidentical trans-
plantation (ClinicalTrials.gov NCT01597778). Future ran-
domized studies to compare outcomes with 7/8 MUD will
also provide essential information for our patients. Perhaps
“alternative” is no longer needed to describe UCBT and 7/8
MUD transplantation.
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